Business Context and Reporting Period
This Form 8-K is a current report filed by Aileron Therapeutics, Inc. (trading symbol: ALRN) on June 5, 2024. The filing addresses corporate governance matters related to the scheduling of the company's 2024 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on shareholder meeting logistics and does not contain financial performance data.
Material Changes
The primary material event is the rescheduling of the 2024 Annual Meeting of Stockholders to August 20, 2024. This date represents a change of more than 30 calendar days from the anniversary of the 2023 annual meeting, triggering specific deadlines for shareholder proposals.
Guidance, Outlook, and Corporate Actions
- Annual Meeting Date: August 20, 2024.
- Shareholder Proposal Deadline: Proposals submitted pursuant to Rule 14a-8 must be received by the Company Secretary by June 15, 2024.
- Director Nominations: Notices for director nominations or other matters under the Bylaws must also be received by June 15, 2024, as the meeting date is delayed by more than 60 days from the prior anniversary.
- Submission Address: 12407 N. Mopac Expy., Suite 250 #390, Austin, Texas 78758.
Key Facts for Investor Verification
- Verify the deadline of June 15, 2024, for submitting Rule 14a-8 proposals or director nominations.
- Confirm the new annual meeting date of August 20, 2024, for voting and attendance planning.
- Note that the registrant name in the filing header is Aileron Therapeutics, Inc., despite the request metadata referencing "Rein Therapeutics, Inc."